Bob and Swing,

Tazeen Ahmad - Merrill Lynch, Pierce, Fenner & Smith, Inc.

Hi, guys thanks for taking my question, just a couple of top level view questions, how long of review period do you expect AFREZZA to have once you respond to the CRL in 3Q of next year. Second question is in terms of the type of partner that you think would be ideal for AFREZZA, are you still thinking that you would like to have a partner who already has a footprint in the diabetes market or are you looking more towards any type of company that has a primary care sales force? Thanks.

Alfred E. Mann - Chairman and Chief Executive Officer

Well, number one is that we still expect a review period of six month with the FDA and that's pretty much set in stone. In regards to partner, I would say they do not necessarily have to be in diabetes. They probably should have some type of endocrine metabolic disease knowledge and presence in terms of their sale forces and yes, we believe that access to the general care physician is an important component, but other than that, we are pretty open-minded in looking at what type of partners we will consider.

http://seekingalpha.com/article/792571-mannkind-s-ceo-discusses-q2-2012-results-earnings-call-transcript?find=six%20month&all=false